Literature DB >> 3802402

Covalent binding of estrogen metabolites to hamster liver microsomal proteins: inhibition by ascorbic acid and catechol-O-methyl transferase.

H Haaf, S A Li, J J Li.   

Abstract

We have studied the irreversible binding of [14C]estradiol to hamster liver and kidney microsomes of castrated hamsters. The binding of estradiol metabolites to kidney microsomes was approximately 25 times lower than seen for liver microsomes, and was not affected by increases in protein or substrate concentration. Our results indicate that this irreversible binding, covalent in nature, is dependent on the metabolism of estrogens to catechols since the absence of NADPH markedly reduces this binding. The irreversible binding was inhibited nearly 70% by addition of catechol-O-methyl transferase (COMT) and S-adenosylmethionine (SAM). Ascorbic acid also inhibited the binding to 85% in a dose-dependent manner. Utilizing a displacement assay to assess the relative covalent binding of different stilbene and steroidal estrogens with homologous radiolabeled hormones, we found that only indenestrol B exhibited greater ability than diethylstilbestrol (DES) to displace [14C]DES from hepatic microsomal proteins. Except for hydroxypropiophenone and beta-dienestrol, all of the stilbene estrogens studied displaced the radioactive DES binding from these liver proteins to a greater extent than estradiol at comparable concentrations. A marked difference was observed in the ability of alpha- and beta-dienestrol to displace [14C]DES. Using radioinert steroidal estrogens to displace [14C]estradiol, we observed that both estriol and deoxoestrone were significantly less effective in displacing radiolabeled estradiol from liver microsomal proteins. Only ethinyl estradiol and 2-hydroxyestradiol displaced greater than 50% of the radioactive hormone at 1-fold excess concentrations. Interestingly, 11 beta-methoxyethinyl estradiol (Moxestrol) exhibited essentially the same ability to bind liver microsomal proteins as estradiol. When estrone and 2,4-dibromoestradiol were used as substrates together, we found the latter compound to be inactive as a substrate for estrogen hydroxylase (ESH) and additionally inhibited the metabolism of estrone to form the catechol metabolite. Data presented herein suggest that the chemically reactive estrogen metabolites responsible for covalent binding of both stilbene and steroidal estrogens are quinoids derived from catechols formed earlier in metabolism. Except for ethinyl estradiol which is a good substrate for liver, but not kidney microsomal ESH, the carcinogenicity data for the hamster kidney with respect to these estrogens is consistent with the covalent binding data presented.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802402     DOI: 10.1093/carcin/8.2.209

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  4 in total

1.  Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro.

Authors:  M Lacort; A M Leal; M Liza; C Martín; R Martínez; M B Ruiz-Larrea
Journal:  Lipids       Date:  1995-02       Impact factor: 1.880

2.  In vitro characterization of estrogen induced Syrian hamster renal tumors: comparison with an immortalized cell line derived from diethylstilbestrol-treated adult hamster kidney.

Authors:  A Gonzalez; T D Oberley; J L Schultz; J Ostrom; J J Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-07       Impact factor: 2.416

3.  Inhibiting effect of ethinylestradiol/levonorgestrel combination on microsomal enzymatic activities in rat liver and kidney.

Authors:  P Czekaj; G Nowaczyk-Dura
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

4.  Site-specific covalent modifications of human insulin by catechol estrogens: Reactivity and induced structural and functional changes.

Authors:  Ming-Chun Ku; Chieh-Ming Fang; Juei-Tang Cheng; Huei-Chen Liang; Tzu-Fan Wang; Chih-Hsing Wu; Chiao-Chen Chen; Jung-Hsiang Tai; Shu-Hui Chen
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.